Friday, April 6, 2012
Molecular Partners AG, of Schlieren, Switzerland, said partner Allergan Inc., of Irvine, Calif., recently reported that AGN-150998/MP0112, an anti-VEGF DARPin compound, was shown to be safe and well tolerated, with no dose-limiting toxicity, after a single administration in Phase IIa trial in macular edema. Preliminary efficacy results suggested a dosing interval of up to three months.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.